The presence of dry eye syndrome and corneal complications in patients with rheumatoid arthritis its association with-174 gene polymorphism for interleukin 6;Výskyt syndromu suchého oka a rohovkových komplikací u pacientů s revmatoidní artritidou a jeho souvislost s polymorfismem -174 genu pro interleukin 6

Ceska a Slovenska Oftalmologie

Volumn 64, Issue 2, 2008, Pages 77-80

  Polanskâ, Veronika ^a   Sery O ^b   Fojtik Z ^a   Hlinomazove Z ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Corneal complications; Dry eye syndrome; Interleukin 6; Polymorphism; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 6;

ARTICLE; CORNEA DISEASE; DRY EYE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CORNEAL DISEASES; DRY EYE SYNDROMES; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 41649114561     PISSN: 12119059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bhadoria, D.,P., Bhadoria, P., Sundaram, K.R. et al.: Ocular manifestation in rheumatoid arthritis. Journal of the Indian Medical Association, 87, 1989: 134-135.
2. Bogllolo, A., Mela, Q., Perplgnano, L. et al.: Ocular involvement in rheumatoid arthritis. Clinica Terapeutica, 142, 1993: 41-46.
3. Cuenca, J., Cuchacovlch, M., Peréz, C. et al.: The -308 polymorphism in the tumour necrosis factor fene promotor region and ex vivo lipopolysacharide -induced TNF expression and cytotoxic activity in Chilean patinets with rheumatoid arthritis. Rheumatology, 42, 2003: 308-313.
4. Harper, S. L., Foster, C. S.: The ocular manifestations of rheumatoid disease. International Ophthalmology Clinics., 38, 1998: 1-19.
5. Choy, E. H., Panayl, G. S.: Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine, 344, 2001: 907-916.
6. Choy, E.: Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 62, 2003: 68-69.
7. Klener, P. et al.: Vnitřní lékař ství. Galen, 2001: 813-822.
8. Pavelka, K.: Biologická léčba revmatoidní artritidy a dalších revmatických onemocnění. Remedia, 5, 2005: 53-65.
9. Pavelka, P., Rovenský, J.: Klinické revmatologie. Galen, 2002: 181-215
10. Pawlik, A., Czerny, B., Dabrowska-Zamojcln, E. et al.: The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone. Polskie Archiwum Medycyny Wewnetrznej, 114, 2005: 843-847.
11. Pflugfelder, S. C., Jones, D., Ji, Z. et al.: Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr. Eye Res., 19, 1999: 201-211.
12. Prada, J., Noelle, B., Baatz, H. et al.: Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Brit. J. Ophthalmol., 87, 2003: 548-550.
13. Robak, T., Gladalska, A., Stepie, H. et al.: Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators of Inflammation, 5, 1998: 347-353.
14. Sankar, V., Brennan, M. T., Kok, M. R. et al.: Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis & Rheumatism. 50, 2004: 2240-2245.
15. Šerý, O., Hladilová, R., Novotný, M. et. al.: Association between -174 G/C polymorphism of interleukin-6 gene and alcoholism. Acta Neuropsychiatrica, 15, 2003: 257-261.
16. Turner, K., Pflugfelder, S. C., Ji, Z. et al.: Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea, 19, 2000: 492-496.